U.S. Markets closed

Immutep to Present at Oppenheimer’s 29th Annual Healthcare Conference

SYDNEY, Australia, March 04, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced its participation in Oppenheimer’s 29th Annual Healthcare Conference.

Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update.

Conference:    Oppenheimer’s 29th Annual Healthcare Conference
     
Dates:    19 March 2019, from 9:10 AM to 9:40 AM Eastern Standard Time
     
Venue:    The Westin New York Grand Central, 212 East 42nd Street, New York, USA
     
Presenter:    Marc Voigt, CEO of Immutep

The presentation is expected to be live webcasted. A link to the webcast will be made available on the Company’s website.

About Immutep

Immutep is listed on the Australian Stock Exchange (IMM), and on the NASDAQ (IMMP) in the US.


For further information please visit www.immutep.com or contact:

U.S. Investors:
Jay Campbell, Chief Business Officer, Immutep Limited
+1 (917) 860-9404; jay.campbell@immutep.com

U.S. Media:
Garth Russell, LifeSci Advisors
+1 (646) 876-3613; garth@lifesciadvisors.com

Australian Investors/Media:
Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; mgregorowski@citadelmagnus.com